Weighing the Benefits of High-Dose Simvastatin against the Risk of Myopathy
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Having reviewed the data on the risk of myopathy, the FDA recommends that the 80-mg dose of simvastatin be used only in patients who have been taking this dose for an extended period without signs or symptoms of clinically significant muscle toxicity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“All currently available statins, except pravastatin, rosuvastatin and pitavastatin, undergo major hepatic metabolism via the CYPs.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [232]
In the citing paper
“A number of important drug interactions with statins have been described that may increase the risk of adverse effects.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [232]
In the citing paper
“Pravastatin does not undergo metabolism through the CYP system, but is metabolized by sulfation and conjugation.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [232]
Citations
Cites
SLCO1B1 Variants and Statin-Induced Myopathy — A Genomewide Study
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801936 · Cited by 2,043
Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group (2010) · The Lancet · doi:10.1016/s0140-6736(10)60310-8 · Cited by 558
Cited by
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
Statins for the primary prevention of cardiovascular disease
Taylor, F., Huffman, M. D., Macedo, A. F., Moore, T. H., Burke, M., Davey Smith, G., Ward, K., Ebrahim, S., & Gay, H. C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004816.pub5 · Cited by 1,934
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.018 · Cited by 1,582
Anderson, T. J., Grégoire, J., Hegele, R. A., Couture, P., Mancini, G. B. J., McPherson, R., Francis, G. A., Poirier, P., Lau, D. C., Grover, S., et al. (2013) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2012.11.032 · Cited by 770
ESC/EAS Guidelines for the management of dyslipidaemias
Catapano, A. L., Reiner, Ž., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.06.028 · Cited by 706
Statins for the primary prevention of cardiovascular disease
Ebrahim, S., Taylor, F. C., & Brindle, P. (2014) · BMJ · doi:10.1136/bmj.g280 · Cited by 333
Resistance and intolerance to statins
Reiner, Ž. (2014) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2014.05.009 · Cited by 225
“This has, together with the data from the US Food and Drug Administration’s (FDA) Adverse Event Reporting Syst em (AERS), caused that the FDA has mandated in 2011 safety-labeling changes for simvas tatin [65].”
Statins and breast cancer prognosis: evidence and opportunities
Ahern, T. P., Lash, T. L., Damkier, P., Christiansen, P. M., & Cronin-Fenton, D. P. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70119-6 · Cited by 203
Elsby, R., Hilgendorf, C., & Fenner, K. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.163 · Cited by 198
DeGorter, M. K., Tirona, R. G., Schwarz, U. I., Choi, Y.-H., Dresser, G. K., Suskin, N., Myers, K., Zou, G., Iwuchukwu, O., Wei, W.-Q., et al. (2013) · Circulation: Cardiovascular Genetics · doi:10.1161/circgenetics.113.000099 · Cited by 195
“The US Food and Drug Administration recommendations advocate for a reduced dose of these statins if moderate CYP3A inhibitors are prescribed and for some potent CYP3A inhibitors contraindicate their use entirely.(33) Finally, our study identified age as a significant factor in predicting the concentrations of atorvast…”
BackgroundOptimizing Drug Outcomes Through Pharmacogenetics: A Case for Preemptive Genotyping
Schildcrout, J. S., Denny, J. C., Bowton, E., Gregg, W., Pulley, J. M., Basford, M. A., Cowan, J. D., Xu, H., Ramirez, A. H., Crawford, D. C., et al. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.66 · Cited by 192
Ballantyne, C. M., Davidson, M. H., MacDougall, D. E., Bays, H. E., DiCarlo, L. A., Rosenberg, N. L., Margulies, J., & Newton, R. S. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.050 · Cited by 175
“Food and Drug Administration (FDA) mandated safetylabeling changes limiting the use of high-dose (80 mg) simvastatin due to safety concerns of muscle injury or myopathy (17).”
BackgroundMancini, G. B. J., Tashakkor, A. Y., Baker, S., Bergeron, J., Fitchett, D., Frohlich, J., Genest, J., Gupta, M., Hegele, R. A., Ng, D. S., et al. (2013) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2013.09.023 · Cited by 173
“Practitioners should remain aware of drug-drug interactions generally related to shared metabolic pathways,115-127 particularly CYP3A4.”
BackgroundCurrent and Emerging Uses of Statins in Clinical Therapeutics: A Review
Davies, J. T., Delfino, S. F., Feinberg, C. E., Johnson, M. F., Nappi, V. L., Olinger, J. T., Schwab, A. P., & Swanson, H. I. (2016) · Lipid Insights · doi:10.4137/lpi.s37450 · Cited by 147
“26,27 Statins are thought to adversely impact muscle tissue by altering mitochondrial function and cellular energy utilization as well as depleting coenzyme Q10 levels.”
BackgroundLee, C. A., O'Connor, M., Ritchie, T. K., Galetin, A., Cook, J., Ragueneau, I., Ellens, H. M., Feng, B., Taub, M. E., Paine, M. F., et al. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.062174 · Cited by 156
“example of the latter is the case of statins where increased exposure can result in myopathy (Egan and Colman, 2011).”
BackgroundHoffman, K. B., Kraus, C., Dimbil, M., & Golomb, B. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042866 · Cited by 124
“Statins have a strong efficacy record in reducing cholesterol, cardiovascular events, and (in secondary prevention for men under age 70), deaths [1,2,3].”
BackgroundMechanisms and assessment of statin‐related muscular adverse effects
Moßhammer, D., Schaeffeler, E., Schwab, M., & Mörike, K. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12360 · Cited by 111
Ephs and ephrins resurface in inflammation, immunity, and atherosclerosis
Funk, S. D., & Orr, A. W. (2012) · Pharmacological Research · doi:10.1016/j.phrs.2012.10.008 · Cited by 104
“Cerivastatin was taken off the market due to high incidence of rhabdomyolysis [14], and the popular drug simvastatin similarly possesses elevated risk for rhabdomyolysis when given at high doses causing the FDA to recently issue a warning on its use [15].”
BackgroundKlug, E., Raal, F. J., Marais, A. D., Taskinen, M.-R., Dalby, A., Schamroth, C., Rapeport, N., Jankelow, D., Blom, D. J., Catsicas, R., et al. (2012) · Journal of Endocrinology Metabolism and Diabetes of South Africa · doi:10.1080/22201009.2012.10872296 · Cited by 86
Muntean, D. M., Thompson, P. D., Catapano, A. L., Stasiolek, M., Fabis, J., Muntner, P., Serban, M.-C., & Banach, M. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2016.09.001 · Cited by 82
Genetic factors affecting statin concentrations and subsequent myopathy: a HuGENet systematic review
Canestaro, W. J., Austin, M. A., & Thummel, K. E. (2014) · Genetics in Medicine · doi:10.1038/gim.2014.41 · Cited by 87
Decreased skeletal muscle mitochondrial DNA in patients with statin-induced myopathy
Stringer, H. A. J., Sohi, G. K., Maguire, J. A., & Côté, H. C. F. (2013) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2012.12.023 · Cited by 79
“There are many risk factors for SIM, including statin dose [19].”
BackgroundThe 2012 SEMDSA Guideline for the Management of Type 2 Diabetes
Amod, A. (2012) · Journal of Endocrinology Metabolism and Diabetes of South Africa · doi:10.1080/22201009.2012.10872276 · Cited by 76
Feng, Q., Wilke, R. A., & Baye, T. M. (2012) · Pharmacogenomics · doi:10.2217/pgs.12.11 · Cited by 68
Use of Administrative Data to Estimate the Incidence of Statin-Related Rhabdomyolysis
Heckbert, S. R. (2012) · JAMA · doi:10.1001/jama.2012.489 · Cited by 61
“These results confirm in a community setting findings from a recent clinical trial that prompted the US Food and Drug Administration to issue a warning about the use of high-dose simvastatin.(4,5) The ICD-9 code for rhabdomyolysis was nonspecific for this ADR, and the resulting misclassification markedly attenuated th…”
ResultLaufs, U., Karmann, B., & Pittrow, D. (2016) · Clinical Research in Cardiology · doi:10.1007/s00392-016-0991-z · Cited by 59
“Indeed, muscle-related adverse events, cognitive and memory problems, and increase of liver enzymes have been reported to occur more frequently at higher doses [8, 30].”
BackgroundThe 2012 SEMDSA Guideline for the Management of Type 2 Diabetes (Revised)
(2012) · Journal of Endocrinology Metabolism and Diabetes of South Africa · doi:10.1080/22201009.2012.10872287 · Cited by 69
Overcoming Challenges With Statin Therapy
Spence, J. D., & Dresser, G. K. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.115.002497 · Cited by 56
Klug, E., Raal, F. J., Marais, A., Smuts, C. M., Schamroth, C., Jankelow, D., Blom, D. J., & Webb, D. A. (2018) · South African Medical Journal · doi:10.7196/samj.2018.v108i11.13383 · Cited by 76
Lehtisalo, M., Taskinen, S., Tarkiainen, E. K., Neuvonen, M., Viinamäki, J., Paile‐Hyvärinen, M., Lilius, T. O., Tapaninen, T., Backman, J. T., Tornio, A., et al. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15485 · Cited by 59
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I. M., Backer, G. D., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Kardiologia Polska · doi:10.5603/kp.2016.0157 · Cited by 62
Shahrezaee, M., Oryan, A., Bastami, F., Hosseinpour, S., Shahrezaee, M. H., & Kamali, A. (2018) · Endocrine · doi:10.1007/s12020-018-1531-6 · Cited by 47
Monitoring of lipids, enzymes, and creatine kinase in patients on lipid-lowering drug therapy
Wiklund, O., Pirazzi, C., & Romeo, S. (2013) · Current Cardiology Reports · doi:10.1007/s11886-013-0397-8 · Cited by 45
“However, the US Food and Drug Administration (FDA) recently concluded that high-dose simvastatin (80 mg/d) is associated with higher risk and should not be used; the interaction between lower doses of simvastatin and other drugs was also emphasized [61].”
BackgroundAcyltransferase inhibitors: a patent review (2010–present)
Ohshiro, T., & Tomoda, H. (2014) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2014.989833 · Cited by 45
“However, clinical data have revealed several problems with their use: i) they only reduce the risk of complications and related death from CV events by 30% [7]; ii) they cause the serious adverse side effect of muscle injury (myopathy and rhabdomyolysis) [8,9]; and iii) they show none or low efficacy against homozygou…”
BackgroundNakashima, Y., & Haneji, T. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072033 · Cited by 45
“Food and Drug Administration (FDA) is recommending limiting the use of the highest approved dose of simvastatin (80 mg) because of the increased risk of muscle damage reported in 2011 [41].”
Isoform-Specific Inhibitors of Acats: Recent Advances and Promising Developments
Ohshiro, T., & Tomoda, H. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.11.158 · Cited by 43
Wang, C., Li, T., Yan, F., Cai, W., Zheng, J., Jiang, X., & Sun, J. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.05.157 · Cited by 45
South African Dyslipidaemia Guideline Consensus Statement
Klug, E. Q. (2012) · South African Medical Journal · doi:10.7196/samj.5502 · Cited by 48
van Staa, T. P., Carr, D. F., O’Meara, H., McCann, G., & Pirmohamed, M. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12367 · Cited by 40
Barrat, E., Zaïr, Y., Ogier, N., Housez, B., Vergara, C., Maudet, C., Lescuyer, J.-F., Bard, J.-M., Carpentier, Y. A., Cazaubiel, M., et al. (2013) · International Journal of Food Sciences and Nutrition · doi:10.3109/09637486.2013.809405 · Cited by 34
“Despite their cardiovascular benefits, all statins are associated with myopathy, ranging in severity from asymptomatic increases in CK, muscle aches or weakness, to fatal rhabdomyolysis (Egan & Colman, 2011).”
BackgroundRole of colesevelam in combination lipid-lowering therapy
Jones, M. R., & Nwose, O. M. (2013) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-013-0037-0 · Cited by 27
“Based on findings such as these, the US Food and Drug Administration placed limitations on the use of the 80-mg dose of simvastatin [23].”
BackgroundAmbrosius, W. T., Polonsky, T. S., Greenland, P., Goff, D. C., Perdue, L., Fortmann, S. P., Margolis, K. L., & Pajewski, N. M. (2012) · Clinical Trials · doi:10.1177/1740774512436882 · Cited by 28
The 2012 SEMDSA Guideline for the Management of type 2 Diabetes
(2012) · Journal of Endocrinology Metabolism and Diabetes of South Africa · doi:10.1080/22201009.2012.10872277 · Cited by 40
Thonusin, C., Apaijai, N., Jaiwongkam, T., Kerdphoo, S., Arunsak, B., Amput, P., Palee, S., Pratchayasakul, W., Chattipakorn, N., & Chattipakorn, S. C. (2019) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2019.114741 · Cited by 26
Chi, C., Jin, W., Yew, P. Y., Lenskaia, T., Loth, M., Pradhan, P. M., Liang, Y., Kurella, P., Mehta, R., Robinson, J. G., et al. (2022) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2022.104029 · Cited by 25
Caveats to aggressive lowering of lipids by specific statins
Koh, K. K., Lim, S. K., Sakuma, I., & Quon, M. J. (2011) · International Journal of Cardiology · doi:10.1016/j.ijcard.2011.09.002 · Cited by 25
“Therefore, the FDAhasmandated safety-labeling changes for Zocor® (simvastatin) [26].”
Soran, H., Adam, S., & Durrington, P. N. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.08.040 · Cited by 23
Impact of New Genomic Technologies on Understanding Adverse Drug Reactions
Maggo, S. D. S., Savage, R. L., & Kennedy, M. A. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0324-9 · Cited by 28
“vascular events between low- and high-dose simvastatin, the US Food and Drug Administration advised that simvastatin 80 mg daily should not be prescribed for patients who had not already tolerated it for a year, and that alternative agents should be used if lipid targets could not be reached with lower doses of simvas…”
BackgroundPalacio-Portilla, E. J., Roquer, J., Amaro, S., Arenillas, J. F., Martín, Ó. A., Castellanos, M., Freijo, M. D. M., Fuentes, B., Pastor, Á. G., Gomis, M., et al. (2020) · Neurología · doi:10.1016/j.nrl.2020.07.027 · Cited by 29
The emerging role of plasma lipidomics in cardiovascular drug discovery
Puri, R., Duong, M., Uno, K., Kataoka, Y., & Nicholls, S. J. (2011) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2012.644041 · Cited by 25
“Already we have observed over time the higher rate of toxicity to high-dose simvastatin (80 mg/day), prompting an FDA warning about the use of this dose of simvastatin [59].”
BackgroundOhshiro, T., Ohtawa, M., Nagamitsu, T., Matsuda, D., Yagyu, H., Davis, M. A., Rudel, L. L., Ishibashi, S., & Tomoda, H. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.227348 · Cited by 23
“…lipoprotein (LDL) cholesterol to the recommended level, and can cause side effects such as an increased risk of muscle injury (myopathy and rhabdomyolysis) and hepatic dysfunction [rise of g-glutamyltransferase and alanine transaminase (ALT)] (Armitage et al., 2010; Egan and Colman, 2011).”
BackgroundStatins for primary prevention and rhabdomyolysis: A nationwide cohort study in France
Coste, J., Billionnet, C., Rudnichi, A., Pouchot, J., Dray‐Spira, R., Giral, P., & Zureik, M. (2018) · European Journal of Preventive Cardiology · doi:10.1177/2047487318776831 · Cited by 22
Ramadan, W. H., & Kabbara, W. K. (2015) · Vascular Health and Risk Management · doi:10.2147/vhrm.s79198 · Cited by 21
Statins: have we found the Holy Grail?
Jeger, R. V., & Dieterle, T. (2012) · Swiss Medical Weekly · doi:10.4414/smw.2012.13515 · Cited by 23
Elsby, R., Hare, V., Neal, H., Outteridge, S. N., Pearson, C., Plant, K., Gill, R. U., Butler, P. J., & Riley, R. J. (2018) · Drug Metabolism and Disposition · doi:10.1124/dmd.118.083832 · Cited by 19
“DDIs with simvastatin acid are of clinical concern as elevated systemic concentrations of statins, due to perturbation of critical disposition pathways, are associated with increased muscle exposure and risk of myopathy or even fatal rhabdomyolysis in extreme cases (Egan and Colman, 2011).”
BackgroundInfluentialVoigt, T., Sebald, H., Schoenauer, R., Levano, S., Girard, T., Hoppeler, H. H., Babiychuk, E. B., & Draeger, A. (2013) · The FASEB Journal · doi:10.1096/fj.12-219345 · Cited by 18
Knežević, S., Filippi-Arriaga, F., Belančić, A., Božina, T., Mršić‐Pelčić, J., & Vitezić, D. (2024) · Diabetology · doi:10.3390/diabetology5040031 · Cited by 20
“Gemfibrozil, if given concomitantly with statin therapy, also has the potential to induce SAMSs [168–170].”
Canestaro, W. J., Brooks, D. G., Chaplin, D., Choudhry, N. K., Lawler, E. V., Martell, L. A., Brennan, T. A., & Wassman, E. R. (2012) · Journal of Personalized Medicine · doi:10.3390/jpm2040158 · Cited by 20
“over SRM motivated the FDA to place new warnings on simvastatin formulations due to the significant risk of both myopathy and rhabdomyolysis with high doses [5,48].”
BackgroundPatent landscape for discovery of promising acyltransferase DGAT and MGAT inhibitors
Zambre, V. P., Khamkar, S. M., Gavhane, D. D., Khedkar, S. C., Chavan, M. R., Pandey, M. M., Sanap, S. B., Patil, R. B., & Sawant, S. D. (2020) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2020.1815707 · Cited by 16
Kinome-wide analysis of the effect of statins in colorectal cancer
Ouahoud, S., Jacobs, R. J., Peppelenbosch, M. P., Fuhler, G. M., Heijmans, J., Diks, S. H., Wildenberg, M. E., Hawinkels, L. J. A. C., Kodach, L. L., Voorneveld, P. W., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01318-9 · Cited by 15
A short-term statin treatment changes the contractile properties of fast-twitch skeletal muscles
Boulanger‐Piette, A., Dufresne, S. S., & Frenette, J. (2016) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-016-1306-2 · Cited by 15
Elsby, R., Coghlan, H., Edgerton, J., Hodgson, D. M., Outteridge, S. N., & Atkinson, H. (2023) · Pharmacology Research & Perspectives · doi:10.1002/prp2.1060 · Cited by 14
Safety Profile of High-Dose Statin Therapy in Geriatric Patients with Stroke
Manocha, D., Bansal, N., Gumaste, P., & Brangman, S. A. (2013) · Southern Medical Journal · doi:10.1097/smj.0000000000000024 · Cited by 13
Nitric oxide prevents atorvastatin‐induced skeletal muscle dysfunction and alterations in mice
D’Antona, G., Mascaro, A., Monopoli, A., Miglietta, D., Ongini, E., & Bottinelli, R. (2012) · Muscle & Nerve · doi:10.1002/mus.23465 · Cited by 12
“Indeed, concern by the FDA has been recently raised about using a high dose of simvastatin because of the risk of developing myopathy.(12) The molecular mechanisms of statin-induced myopathy have not yet been determined.”
BackgroundDislipidemia y riesgo vascular. Una revisión basada en nuevas evidencias
Pallarés‐Carratalá, V., Fuster, V. P., & Rocati, D. V. G. (2015) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2014.10.015 · Cited by 31
Klug, E., Raal, F. J., Marais, A., Taskinen, M.-R., Dalby, A., Schamroth, C., Rapeport, N., Jankelow, D., Blom, D. J., Catsicas, R., et al. (2013) · South African Family Practice · doi:10.1080/20786204.2013.10874296 · Cited by 12
Fahim, T. M., Mohamed, M. A. E. H., Abdelrahman, S. S. M., & Lotfy, D. M. (2023) · Dose-Response · doi:10.1177/15593258231179900 · Cited by 12
“Anemia, infection, and a variety of other illnesses can all be diagnosed with complete blood picture.(8,9) In medicine, there is a lack of understanding of hematological indices and the changes caused by various gamma-radiation dosages.”
BackgroundInitiation of Statin Therapy: Are There Age Limits?
Desai, D. A., Zakaria, S., & Ouyang, P. (2011) · Current Atherosclerosis Reports · doi:10.1007/s11883-011-0220-1 · Cited by 14
Drug interactions of antihypertensive agents
Opie, L. H. (2012) · South African Family Practice · doi:10.1080/20786204.2012.10874206 · Cited by 10
Palacio-Portilla, E. J., Roquer, J., Amaro, S., Arenillas, J. F., Martín, Ó. A., Castellanos, M., Freijo, M. M., Fuentes, B., Pastor, Á. G., Gomis, M., et al. (2022) · Neurología (English Edition) · doi:10.1016/j.nrleng.2020.07.021 · Cited by 12
Rabdomiolisis secundaria a simvastatina y fenofibrato
Forcadell-Peris, M. J., & de Diego‐Cabanes, C. (2014) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2014.01.007 · Cited by 9
Muñoz, M. A., Tonning, J. M., Brinker, A. D., Delaney, J. A., Gatti, J. C., & Avigan, M. (2016) · Pharmaceutical Medicine · doi:10.1007/s40290-016-0162-6 · Cited by 10
“The FDA’s review of data from large clinical trials of high doses of statins indicates that the incidence of myopathy was approximately three times higher with the 80 mg dose of simvastatin than with superior LDL-lowering doses of rosuvastatin and atorvastatin [37].”
BackgroundBig Data Cohort Extraction to Facilitate Machine Learning to Improve Statin Treatment
Chi, C., Wang, J., Clancy, T. R., Robinson, J. G., Tonellato, P. J., & Adam, T. J. (2016) · Western Journal of Nursing Research · doi:10.1177/0193945916673059 · Cited by 8
Anderson, T. J., Grégoire, J., Hegele, R. A., Couture, P., McPherson, R., Francis, G. A., Poirier, P., Lau, D. C. W., Grover, S. A., Carpentier, A. C., et al. (2013) · Cited by 9
Huang, X., & Chen, D. Y. ‐. (2012) · ChemMedChem · doi:10.1002/cmdc.201200287 · Cited by 5
Maher, V. M. G., Gallagher, J., Agar, R., Griffin, D. G., Colwell, N. S., O’Connor, P., McAdam, B. F., TOMKIN, G. H., Owens, D., Ryan, M., et al. (2023) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-023-03277-x · Cited by 5
“Suggested actions regarding myopathy [12, 13] are revealed in Fig.”
BackgroundWhat are the benefits and drawbacks of statins in carotid artery disease? A perspective review
Said, S., Dardik, A., & Chaar, C. I. O. (2023) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2023.2286011 · Cited by 6
“On the other hand, statin therapy may interfere with the catabolism of other medicines metabolized by the same enzyme system [74,78,80].”
BackgroundEffect of plant sterols compared with ezetimibe on oxidative stress in patients treated with statins
Bertolami, A., Botelho, P. B., Macedo, L. F. L., Abdalla, D. S. P., Faludi, A. Á., Galasso, M., & de Castro, I. A. (2014) · Journal of Functional Foods · doi:10.1016/j.jff.2014.05.018 · Cited by 5
Interpretation of Unexpectedly High Levels of Endocrine Tumor Markers
Yu, R. (2018) · Endocrine Practice · doi:10.4158/ep-2018-0166 · Cited by 5
Lipid-modifying and antiatherosclerotic drugs
Gotto, A. M., & Opie, L. H. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-3322-4.00019-3 · Cited by 6
Asrorovna, R. A., Мурадова, Р. Р., Negmatovich, T. K., & Нуралиева, Р. М. (2020) · International Journal of Current Research and Review · doi:10.31782/ijcrr.2020.121414 · Cited by 4
Polypharmacology in Clinical Applications: Cardiovascular Polypharmacology
Wang, Z., & Yang, B. (2022) · Springer eBooks · doi:10.1007/978-3-031-04998-9_4 · Cited by 4
Weeks, G. R., Fyfe, R., Amerena, J. V., & George, J. (2012) · Journal of Pharmacy Practice and Research · doi:10.1002/j.2055-2335.2012.tb00124.x · Cited by 4
Role of Aggressive LDL Reduction in Patients With Coronary Heart Disease
Benge, C. D., Markley, B. M., & McFarland, M. S. (2011) · Southern Medical Journal · doi:10.1097/smj.0b013e31823c4242 · Cited by 4
“In 2001, the Food and Drug Administration mandated safety-labeling changes to decrease substantially the use of 80-mg simvastatin and instead to use other intensive therapies such as atorvastatin and rosuvastatin, which have a better musculoskeletal safety profile.(29) The decision to use moderate intensity therapy wi…”
Kuller, L. H., & Edmundowicz, D. (2011) · The Open Epidemiology Journal · doi:10.2174/1874297101104010152 · Cited by 4
Extended-release niacin/laropiprant for lipid management: observational study in clinical practice
Steinhagen‐Thiessen, E., Dänschel, W., Buffleben, C., Smolka, W., Pittrow, D., & Hildemann, S. K. (2013) · International Journal of Clinical Practice · doi:10.1111/ijcp.12088 · Cited by 3
Jain, K. K. (2021) · Springer eBooks · doi:10.1007/978-3-030-73503-6_31 · Cited by 3
Pharmacological lipid lowering for prevention of cardiovascular disease in older adults
Wiklund, O., Pirazzi, C., & Romeo, S. (2013) · Clinical Practice · doi:10.2217/cpr.13.83 · Cited by 2
Pedro‐Botet, J., & Pintó, X. (2015) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2015.10.006 · Cited by 2
Lipidomics: Opportunities to Identify New Causal Mechanisms and Therapeutics for Atherosclerosis
Puri, R., Duong, M., Kataoka, Y., Uno, K., & Nicholls, S. J. (2012) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-012-0284-7 · Cited by 1
Mermis, J. D., & Simpson, S. Q. (2014) · CHEST Journal · doi:10.1378/chest.14-2225 · Cited by 1
SECONDARY PHARMACOLOGICAL PREVENTION OF CARDIOVASCULAR DISEASES: OUR ABILITY IN CLINICAL PRACTICE
Филиппов, Е. В., & Yakushin, S. S. (2012) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2012-8-6-788-797 · Cited by 1
Vitamin D Supplementation reduces Atorvastatin induced Myopathy in Dyslipedemic patients
Nadeem, M., Alam, S. S., Zahra, S. M.-E.-N., Daniyal, S. M., Zia, H., Saqib, M., & Nadeem, M. (2022) · Pakistan Journal of Medical and Health Sciences · doi:10.53350/pjmhs2216265 · Cited by 1
South African dyslipidaemia guideline consensus statement
Klug, E., Raal, F. J., Marais, A., Taskinen, M., Dalby, A., Schamroth, C., Rapeport, N., Jankelow, D., Blom, D. J., Catsicas, R., et al. (2012) · SA Heart · doi:10.24170/9-2-1855 · Cited by 1
Pharmacometrics of Hyperlipidemia
Emery, M. G., Haughney, P. C., & Gibbs, J. P. (2014) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-1-4939-1304-6_19
Metabolic Regulation of Endothelial Dysfunction and Cardiovascular Risk
Young, J. M. (2012) · Otago University Research Archive (University of Otago) · Cited by 1
DISCOVERY AND DEVELOPMENT OF ISOZYME‐SELECTIVE INHIBITORS INVOLVED IN LIPID METABOLISM
Ohshiro, T., & Tomoda, H. (2013) · Wiley eBooks · doi:10.1002/9781118739907.ch2
Gohlke, H., Albus, C., Bönner, G., Darius, H., Eckert, S., Gohlke-Bärwolf, C., Gysan, D. B., Hahmann, H., Halle, M., Hambrecht, R., et al. (2013) · Der Kardiologe · doi:10.1007/s12181-012-0468-x · Cited by 1
“Bei Einsatz des in Deutschland bisher am häufigsten verordneten Simvastatins ist zu beachten, dass wegen des Rhabdomyolyserisikos und der Häufigkeit von muskulären Beschwerden von der bisher geltenden Höchstdosis (80 mg/Tag) abgeraten wird und darüber hinaus besonders auf eine Dosisanpassung bei gleichzeitiger Verabre…”
Background
Metadata
- Authors
- Egan, A., & Colman, E.
- Affiliations
- United States Food and Drug Administration (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-07-28
- Volume
- 365
- Issue
- 4
- Pages
- 285-287
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1993796214
- Cited by
- 113
- References
- 3
- Citations by year
- 2025: 1 · 2024: 1 · 2023: 7 · 2022: 5 · 2021: 2 · 2020: 3 · 2019: 4 · 2018: 7 · 2016: 11 · 2015: 6 · 2014: 13 · 2013: 22 · 2012: 23
- FWCI
- 21.54
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- simvastatin, high-intensity statin therapy, myopathy, rhabdomyolysis, muscle toxicity, drug safety, risk-benefit assessment
- MeSH terms
- Anticholesteremic Agents, Creatine Kinase, Drug Interactions, Drug Labeling, Humans, Muscular Diseases, Risk, United States, United States Food and Drug Administration, Drug Approval, Simvastatin, Dyslipidemias
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.